Psychiatry
RCT | Reducing social media use improves appearance and weight esteem in youth with emotional distress
3 Mar, 2023 | 14:04h | UTCSummary: The article discusses a randomized controlled trial conducted on 220 participants aged 17-25 to examine the effects of reducing smartphone social media use (SMU) on appearance and weight esteem in youth with emotional distress. The participants were divided into an intervention group (limited to 1 hr/day SMU) and a control group (unrestricted SMU). The study found that reducing SMU improved appearance and weight esteem in the intervention group, while the control group showed no significant change. The authors concluded that reducing SMU may be a feasible and effective method of improving body image in a vulnerable youth population and should be evaluated as a potential component in treating body image-related disturbances. It is worth noting, however, that the impossibility of blinding participants and the subjective nature of the endpoints make it difficult to draw definitive conclusions on the subject.
News Release: Reducing social media use significantly improves body image in teens, young adults – American Psychological Association
Commentary: How to help young people limit screen time — and feel better about how they look – NPR
M-A | Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata
2 Mar, 2023 | 12:59h | UTCPrevalence and Odds of Depressive and Anxiety Disorders and Symptoms in Children and Adults With Alopecia Areata: A Systematic Review and Meta-analysis – JAMA Dermatology (link to abstract – $ for full-text)
Commentary: Anxiety, Depressive Disorder Prevalence Greater Among Alopecia Areata Patients – HCP Live
RCT | Electrostimulation with the Alpha-Stim AID device is not better than sham treatment in major depression
2 Mar, 2023 | 12:49h | UTCCommentary: Active AID Device Not More Effective Than Sham at Improving Depressive Symptoms – Neurology Advisor
Review | Borderline personality disorder
1 Mar, 2023 | 14:04h | UTCBorderline Personality Disorder: A Review – JAMA (free for a limited period)
JAMA Patient Page: Borderline Personality Disorder
M-A | Efficacy of brief behavioral therapy for insomnia in older adults with chronic insomnia
1 Mar, 2023 | 13:55h | UTC
RCT | Efficacy of oral vs. long-acting antipsychotic treatment in patients with early-phase schizophrenia
1 Mar, 2023 | 13:38h | UTCEfficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST) – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary: No benefit of long-acting antipsychotics in schizophrenia? – MDedge
Physicians are more burned out than ever — here’s what can be done about it
28 Feb, 2023 | 13:57h | UTCPhysicians Are More Burned Out Than Ever—Here’s What Can Be Done About It – JAMA (free for a limited period)
Related Report: Addressing Health Worker Burnout – The U.S. Surgeon General’s Advisory on Building a Thriving Health Workforce
Related:
AAP Clinical Report | Physician health and wellness.
M-A | Physicians suffering burnout are twice as likely to be involved in patient safety incidents.
Systematic Review | Predictors of burnout among healthcare providers.
Physician Well-being 2.0: Where Are We and Where Are We Going? – Mayo Clinic Proceedings
Assessment of Risk Factors for Suicide Among US Health Care Professionals
Beyond Burnout: Docs Decry ‘Moral Injury’ From Financial Pressures of Health Care
Hospital administration response to physician stress and burnout – Journal of Hospital Practice
Opinion: It’s Time to Talk About Physician Burnout and Moral Injury
Systematic Review: Effect of Organization-Directed Workplace Interventions on Physician Burnout
The 3 Causes Of Physician Burnout (And Why There’s No Simple Solution) – Forbes
Physician Burnout: A Global Crisis
The Burnout Crisis in American Medicine – The Atlantic
Physician burnout costs up to $17B a year, task force says – HealthcareDive
Systematic Review: Prevalence of Burnout Among Physicians
Association Between Physician Burnout and Patient Safety, Professionalism, and Patient Satisfaction
RCT | Single-dose psilocybin-assisted therapy in major depressive disorder
28 Feb, 2023 | 13:26h | UTCRelated:
Phase 2 RCT | Single-dose Psilocybin for a treatment-resistant episode of major depression.
Research: “Magic mushrooms” for treatment-resistant depression
Commentary on Twitter
?New placebo-controlled, double-blind, RCT: Single-dose #psilocybin-assisted therapy in #majordepressivedisorder
Results suggest that a single dose of psilocybin significantly reduces depressive symptoms compared to placebo for at least 2 weekshttps://t.co/Ps43rxHv6r pic.twitter.com/Qc8xSgnalw
— eClinicalMedicine – The Lancet Discovery Science (@eClinicalMed) January 18, 2023
Review | Young-onset dementia diagnosis, management and care
24 Feb, 2023 | 13:37h | UTC
M-A | Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics
23 Feb, 2023 | 13:26h | UTCSummary: This study aimed to evaluate the mid- to long-term metabolic side effects of 31 antipsychotics in persons with schizophrenia by analyzing 137 eligible randomized controlled trials with 35,007 participants. The primary outcome was weight gain, with secondary outcomes including fasting glucose, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. The study found that antipsychotic drugs differ in their propensity to induce metabolic side effects. Chlorpromazine, clozapine, olanzapine, and zotepine produced the most weight gain. The confidence in the evidence ranged from low to moderate. The study suggests that differences in weight gain were more pronounced than previously published short-term data and that weight gain is most pronounced at the beginning of treatment and then remains stable.
Article: Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials – World Psychiatry (free for a limited period)
SR | Antipsychotic exposure is an independent risk factor for breast cancer
17 Feb, 2023 | 12:41h | UTC
Pediatric edible cannabis exposures and acute toxicity in the US: 2017–2021
16 Feb, 2023 | 15:00h | UTCPediatric Edible Cannabis Exposures and Acute Toxicity: 2017–2021 – Pediatrics
Commentaries:
The Number of American Kids Eating Cannabis Has Surged Dramatically – Science Alert
2017 to 2021 Saw Increase in Pediatric Edible Cannabis Exposure – HealthDay
M-A | Cost-effectiveness of internet interventions compared with treatment as usual for people with mental disorders
16 Feb, 2023 | 14:43h | UTC
SR | The effect of parental leave on parents’ mental health
15 Feb, 2023 | 15:44h | UTCInvited Commentary: Paid parental leave and mental health: the importance of equitable policy design – The Lancet Public Health
News Release: Generous parental leave schemes protect against poorer mental health – Stockholm University / News Medical
Consensus Paper | ED management of patients with alcohol intoxication, alcohol withdrawal, and alcohol use disorder
14 Feb, 2023 | 11:05h | UTC
Diagnostic Study | Level of attention to motherese speech as an early marker of autism spectrum disorder
14 Feb, 2023 | 11:04h | UTCSummary: A study was conducted to determine if levels of attention to motherese speech can be used as a diagnostic marker for autism spectrum disorder (ASD) and if they are associated with social and language abilities. The study involved 653 toddlers aged 12 to 48 months and used gaze-contingent eye tracking to measure attention to motherese speech. The results showed that toddlers without ASD had high levels of fixation on motherese speech, while those with ASD had significantly reduced levels. If a toddler fixated on motherese speech at or below 30%, the probability of them being accurately diagnosed with ASD was 94%, and it was also associated with reduced social and language abilities. The findings suggest that attention to motherese speech may be a diagnostic and prognostic marker of ASD.
(By ChatGPT, reviewed and edited)
Commentaries:
Toddlers’ Attention to ‘Motherese’ Could Give Clues to Autism – HealthDay
Cohort Study | In utero exposure to ADHD medication does not seem to result in worse offspring neurodevelopmental outcomes
14 Feb, 2023 | 10:54h | UTCSummary: The authors conducted a study to investigate the long-term effects of in utero exposure to ADHD medication (methylphenidate, amphetamine, dexamphetamine, lisdexamphetamine, modafinil, atomoxetine, clonidine) on offspring. The study followed 1,068,073 liveborn singletons from 1998 to 2018 and compared the outcomes of children whose mothers continued or discontinued ADHD medication during pregnancy. The main outcomes were neurodevelopmental psychiatric disorders, impairments in vision or hearing, epilepsy, seizures, or growth impairment during childhood or adolescence. After adjustment for demographic and psychiatric characteristics of the mother, no increased risk of any developmental disorders was found in offspring exposed to ADHD medication compared to those not exposed. The results provide reassurance for women with ADHD who depend on medication and consider continuing it during pregnancy.
(By ChatGPT, reviewed and edited)
Article: In utero exposure to ADHD medication and long-term offspring outcomes – Molecular Psychiatry (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
In-utero exposure to ADHD medication is not associated with long-term adverse neurodevelopmental disorders and growth restriction in the offspring.
Read the thread below ?on our new paper just published in @molpsychiatry
? https://t.co/MKZ0aeFnhU#ADHD— Kathrine Bang Madsen (@Kathrine_BaMa) February 9, 2023
Consensus Paper | Biological treatment of bipolar disorder during the acute, maintenance, and mixed phases
10 Feb, 2023 | 13:50h | UTCRelated:
Bipolar disorder: assessment and management – National Institute for Health and Care Excellence
Korean Medication Algorithm Project for Bipolar Disorder 2022: comparisons with other treatment guidelines
10 Feb, 2023 | 13:49h | UTC
Cohort Study | Associations between betablockers and psychiatric and behavioral outcomes
10 Feb, 2023 | 13:47h | UTC
Phase 1b RCT | Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia
8 Feb, 2023 | 12:23h | UTCEmraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial – The Lancet (link to abstract – $ for full-text)
Commentary: Emraclidine is safe and well-tolerated for the treatment of schizophrenia – 2 Minute Medicine
Commentary on Twitter (thread – click for more)
Up to 1/3 of patients with #schizophrenia do not respond to current treatments, and there remains a need for novel approaches that balance efficacy against side-effects.
This phase 1b study assessed the safety and tolerability of emraclidine ? https://t.co/WMcArqDK1C
— The Lancet (@TheLancet) December 28, 2022
M-A | Efficacy of treatments for children, adolescents, and young adults with Tourette’s syndrome
8 Feb, 2023 | 12:13h | UTCComparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette’s syndrome: a systematic review and network meta-analysis – The Lancet Child & Adolescent Health (link to abstract – $ for full-text)
Commentary on Twitter
Treatment recommendations are inconsistent for #Tourette syndrome.
New network meta-analysis by @luis_farhat & team shows that #antipsychotics are the most efficacious, while α-2 agonists are also more efficacious than placebohttps://t.co/awYHWUJA3v
— The Lancet Child & Adolescent Health (@LancetChildAdol) December 19, 2022
Cohort Study | The use of 5-alfa-reductase inhibitors may increase the risk of depression, but not dementia
7 Feb, 2023 | 13:35h | UTCAssociation of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide – JAMA Network Open
Commentary: 5α-Reductase Inhibitors Linked to Depression, but Not Dementia – HealthDay
Cohort Study | Association between antiepileptic drugs and incident Parkinson disease
3 Feb, 2023 | 13:51h | UTCAssociation Between Antiepileptic Drugs and Incident Parkinson Disease in the UK Biobank – JAMA Neurology (link to abstract – $ for full-text)
Commentary on Twitter
This study using @uk_biobank data found evidence of an association between anti-epileptic drugs and incident #ParkinsonDisease. https://t.co/58PMlWQUYU
— JAMA Neurology (@JAMANeuro) December 28, 2022
M-A | Depressive symptoms in individuals with persistent postconcussion symptoms
3 Feb, 2023 | 13:48h | UTCCommentary: Significant Link Seen for Persistent Postconcussion Symptoms, Depression – HealthDay
Commentary on Twitter
Patients with persistent postconcussion symptoms are at increased risk of experiencing symptoms of depression. Post-injury support and interventions targeting mental health are necessary for optimal outcomes. https://t.co/7KiletIsf6
— JAMA Network Open (@JAMANetworkOpen) December 27, 2022